title: Soluble intercellular adhesion molecule-I (sICAM-I) in serum and cerebrospinal fluid of demyelinating diseases of the central and peripheral nervous system.
abstract: Serum and cerebrospinal fluid (CSF) soluble intercellular adhesion molecule-I (ICAM-I) levels were evaluated (ELISA) in 22 untreated and 13 corticosteroid-treated active relapsing remitting (RR) Multiple Sclerosis (MS), in 10 untreated and 10 corticosteroid-treated Guillain-Barré syndrome (GBS) and in 17 non-inflammatory neurological diseases (NIND). Twenty-eight clinically inactive RR MS were assayed for serum sICAM-I before and after 3 months treatment of 8 MIU rIFN beta-Ib taken s.c. every other day. High sICAM-I serum levels above the NIND values were found in untreated clinically active MS and in untreated GBS (P < 0.05) but not in the untreated clinically inactive MS group. The active MS group showed significantly (P = 0.0001) higher sICAM-I serum levels if compared to the inactive group. Corticosteroid-treated active MS and GBS patients showed lower (P < 0.05) serum sICAM-I levels than the corresponding untreated groups. Serum sICAM-I levels after 3 months of rIFN beta-Ib treatment (P < 0.0001, paired t-test) resulted increased compared to pretreatment values in MS. The mean values of CSF/serum sICAM-I:CSF/serum Albumin ratios (sICAM-I Index) in active untreated MS patients were higher compared to NIND (P < 0.005) and to corticosteroid-treated MS group (P = 0.01). sICAM Index values in GBS did not differ from those in NIND. The results seem to suggest potential roles for serum sICAM-I in downregulating the ongoing inflammatory response at the blood-brain barrier level and for CSF sICAM-I in the maintenance of a central nervous system local immune response.
authors.affiliation: Institute of Clinical Neurology, University of Bari, Italy.
authors.forename: M
authors.initials: M
authors.lastname: Trojano
authors.forename: C
authors.initials: C
authors.lastname: Avolio
authors.forename: M
authors.initials: M
authors.lastname: Ruggieri
authors.forename: F
authors.initials: F
authors.lastname: De Robertis
authors.forename: F
authors.initials: F
authors.lastname: Giuliani
authors.forename: D
authors.initials: D
authors.lastname: Paolicelli
authors.forename: P
authors.initials: P
authors.lastname: Livrea
mesh_terms: D000305:Adrenal Cortex Hormones / Q000008:administration & dosage; D000328:Adult; D000368:Aged; D001812:Blood-Brain Barrier; D015815:Cell Adhesion Molecules / Q000097:blood / Q000134:cerebrospinal fluid*; D002490:Central Nervous System / Q000378:metabolism; D005260:Female; D006801:Humans; D016899:Interferon-beta / Q000008:administration & dosage; D008297:Male; D008875:Middle Aged; D009103:Multiple Sclerosis / Q000097:blood* / Q000134:cerebrospinal fluid* / Q000188:drug therapy; D017933:Peripheral Nervous System / Q000378:metabolism; D011129:Polyradiculoneuropathy / Q000097:blood* / Q000134:cerebrospinal fluid* / Q000188:drug therapy; D011994:Recombinant Proteins / Q000008:administration & dosage; D012995:Solubility
chemical_list: D000305:Adrenal Cortex Hormones; D015815:Cell Adhesion Molecules; D011994:Recombinant Proteins; D016899:Interferon-beta